Cover Image
市場調查報告書

麻痺:開發平台分析

Paralysis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 251564
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
麻痺:開發平台分析 Paralysis - Pipeline Review, H2 2015
出版日期: 2015年09月30日 內容資訊: 英文 51 Pages
簡介

所謂麻痺是指一個以上肌肉喪失功能,不只是運動神經,感覺神經損傷其週遭部位也會喪失知覺。麻痺有完全及局部性麻痺,譬如半身或雙腿的下半身麻痺。包含兩腳的下半身麻痺稱作下肢麻痺、手與腳則稱為四肢麻痺。幾乎所有的麻痺都是由於腦中風、脊髓損傷和頭部骨折等原因造成的。

本報告提供麻痺的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

麻痺 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

治療藥的開發企業

  • 旭化成製藥
  • Immunome Inc.
  • Marathon Pharmaceuticals, LLC
  • Neuralstem, Inc.
  • ReqMed Company, Ltd.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BNZ-1321
  • elcatonin
  • flunarizine hydrochloride
  • Monoclonal Antibody Conjugates for Paralysis
  • NSI-566
  • pentosan polysulfate sodium
  • REM-1086

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7186IDB

Summary

Global Markets Direct's, 'Paralysis - Pipeline Review, H2 2015', provides an overview of the Paralysis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Paralysis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paralysis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Paralysis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Paralysis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Paralysis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Paralysis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Paralysis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Paralysis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Paralysis Overview
    • Therapeutics Development
      • Pipeline Products for Paralysis - Overview
      • Pipeline Products for Paralysis - Comparative Analysis
  • Paralysis - Therapeutics under Development by Companies
  • Paralysis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Paralysis - Products under Development by Companies
  • Paralysis - Companies Involved in Therapeutics Development
    • Asahi Kasei Pharma Corp.
    • Immunome Inc.
    • Marathon Pharmaceuticals, LLC
    • Neuralstem, Inc.
    • Ultragenyx Pharmaceutical Inc.
  • Paralysis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BNZ-1321 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • elcatonin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • flunarizine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Paralysis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REM-1086 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UX-007 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Paralysis - Recent Pipeline Updates
  • Paralysis - Dormant Projects
  • Paralysis - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Paralysis, H2 2015
  • Number of Products under Development for Paralysis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Paralysis - Pipeline by Asahi Kasei Pharma Corp., H2 2015
  • Paralysis - Pipeline by Immunome Inc., H2 2015
  • Paralysis - Pipeline by Marathon Pharmaceuticals, LLC, H2 2015
  • Paralysis - Pipeline by Neuralstem, Inc., H2 2015
  • Paralysis - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Paralysis Therapeutics - Recent Pipeline Updates, H2 2015
  • Paralysis - Dormant Projects, H2 2015
  • Paralysis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Paralysis, H2 2015
  • Number of Products under Development for Paralysis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top